Illumina Inc. (NASDAQ:ILMN) Director Daniel Bradbury sold 600 shares of the stock in a transaction on Friday, October 7th. The stock was sold at an average price of $184.36, for a total value of $110,616.00. Following the transaction, the director now owns 17,065 shares of the company’s stock, valued at $3,146,103.40. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Daniel Bradbury also recently made the following trade(s):

  • On Wednesday, September 14th, Daniel Bradbury sold 600 shares of Illumina stock. The stock was sold at an average price of $171.25, for a total value of $102,750.00.
  • On Wednesday, August 17th, Daniel Bradbury sold 600 shares of Illumina stock. The stock was sold at an average price of $168.42, for a total value of $101,052.00.

Shares of Illumina Inc. (NASDAQ:ILMN) opened at 136.18 on Thursday. Illumina Inc. has a 12 month low of $127.10 and a 12 month high of $196.47. The stock’s 50 day moving average price is $172.97 and its 200 day moving average price is $156.29. The firm has a market cap of $19.96 billion, a price-to-earnings ratio of 46.64 and a beta of 0.47.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Tuesday, July 26th. The life sciences company reported $0.86 EPS for the quarter, beating analysts’ consensus estimates of $0.73 by $0.13. The firm earned $600 million during the quarter, compared to the consensus estimate of $31.91 million. Illumina had a return on equity of 23.69% and a net margin of 18.73%. Illumina’s revenue for the quarter was up 11.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.80 earnings per share. Equities research analysts predict that Illumina Inc. will post $3.53 earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

A number of equities analysts have recently weighed in on ILMN shares. JPMorgan Chase & Co. increased their price target on Illumina from $185.00 to $200.00 and gave the stock an “overweight” rating in a report on Wednesday, July 27th. Cantor Fitzgerald restated a “hold” rating on shares of Illumina in a report on Wednesday, June 29th. Vetr cut Illumina from a “buy” rating to a “hold” rating and set a $187.86 target price for the company. in a report on Monday. BTIG Research restated a “neutral” rating on shares of Illumina in a report on Wednesday. Finally, Argus raised their target price on Illumina from $175.00 to $185.00 and gave the company a “buy” rating in a report on Monday, August 8th. Two research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $157.50.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Physicians Financial Services Inc. increased its position in shares of Illumina by 2,121.2% in the second quarter. Physicians Financial Services Inc. now owns 733 shares of the life sciences company’s stock worth $103,000 after buying an additional 700 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its position in shares of Illumina by 25.0% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 789 shares of the life sciences company’s stock worth $110,000 after buying an additional 158 shares in the last quarter. Fuller & Thaler Asset Management Inc. acquired a new position in shares of Illumina during the second quarter worth approximately $112,000. Ropes Wealth Advisors LLC increased its position in shares of Illumina by 72.6% in the second quarter. Ropes Wealth Advisors LLC now owns 863 shares of the life sciences company’s stock worth $121,000 after buying an additional 363 shares in the last quarter. Finally, Checchi Capital Advisers LLC increased its position in shares of Illumina by 2.4% in the second quarter. Checchi Capital Advisers LLC now owns 958 shares of the life sciences company’s stock worth $134,000 after buying an additional 22 shares in the last quarter. 95.22% of the stock is owned by hedge funds and other institutional investors.

About Illumina

Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.

5 Day Chart for NASDAQ:ILMN

Receive News & Stock Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related stocks with our FREE daily email newsletter.